StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS)

Research analysts at StockNews.com started coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays decreased their price objective on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th.

Cellectis Stock Performance

Shares of NASDAQ:CLLS opened at $1.71 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.78 and a quick ratio of 1.78. The business’s fifty day moving average price is $1.91 and its two-hundred day moving average price is $2.09. Cellectis has a fifty-two week low of $1.70 and a fifty-two week high of $3.77. The stock has a market capitalization of $95.05 million, a price-to-earnings ratio of -1.32 and a beta of 3.09.

Cellectis (NASDAQ:CLLS) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The firm had revenue of $18.05 million during the quarter, compared to analyst estimates of $5.00 million. Cellectis had a negative net margin of 234.39% and a negative return on equity of 74.55%. During the same quarter in the prior year, the firm posted ($0.31) EPS. As a group, analysts predict that Cellectis will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Cellectis

A number of hedge funds have recently added to or reduced their stakes in CLLS. XTX Topco Ltd acquired a new position in shares of Cellectis during the second quarter worth approximately $29,000. First Affirmative Financial Network acquired a new position in Cellectis during the 3rd quarter worth $45,000. Principal Financial Group Inc. boosted its position in Cellectis by 2.9% in the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after buying an additional 12,467 shares during the last quarter. Finally, Long Focus Capital Management LLC boosted its position in Cellectis by 2.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after buying an additional 130,000 shares during the last quarter. Institutional investors own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.